0000000000555629
AUTHOR
Günther Schellong
showing 2 related works from this author
Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria
2013
In Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease-specific first-line clinical trials or interim registries. Essential components are a pediatric cancer registry and centralized reference laboratories, imaging review, and tumor board assistance. The five-year overall survival rate in countries where such infrastructures are established has improved from 80% since 1995. Today, treatment intensity is tailored to the individual patient's risk to provide the highest chances of survival while minimizing deleterious late effects. Multicenter clinical trials are internationalized and serve as platforms for further improvements by novel drugs an…
Surface Marker Analysis by Monoclonal Antibodies: A Valuable Technique in Childhood Acute Myeloid Leukemia
1987
A considerable number of monoclonal antibodies (MoAbs) with myeloid activity have been described during the last few years (summarized in [1]). These MoAbs have been applied to the study of normal myeloid differentiation, as well as to the surface marker analysis of acute myeloid leukemia (AML) [2–6]. Although there is a strong tendency for morphological differentiation to correspond to surface antigen differentiation of malignant myeloid cells [2, 3], a recent report has failed to correlate the FAB classification system with immunologic categories of AML [6].